BioCentury
ARTICLE | Clinical News

Intrarosa regulatory update

November 17, 2016 10:45 PM UTC

FDA approved an NDA for Intrarosa prasterone from Endoceutics to treat moderate to severe dyspareunia, a symptom of vulvar and vaginal atrophy (VVA), in postmenopausal women. The once-daily vaginal in...

BCIQ Company Profiles

Endoceutics Inc.